A Study to Evaluate Precision Pharmacogenomics in Cancer Patients

Overview

About this study

THe purpose of this study is to examine the current and (potential) future therapeutic relevance of pharmacogenomics (PGx) testing for a cohort of cancer patients in order to improve quality of life (QOL) in patients receiving clinical care at Mayo Clinic.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

Inclusion Criteria:

  • Patient enrolled to Mayo Clinic IRB: 18-000326
  • Patients with stage 3 or 4 breast, colorectal, prostate/GU, pancreato-biliary, brain, melanoma, and ovarian cancer.
  • Individuals have agreed to participate and signed the study informed consent form.

Exclusion Criteria: 

  • Patients with cancer types other than the ones mentioned above
  • Patient with psychiatric illness, or situations that would limit compliance with the study requirements or the ability to willingly give written informed consent.
  • Previous PGx testing with results available within Mayo Clinic EMR.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Niloy Jewel Samadder, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20462461

Mayo Clinic Footer